Pharmacoepigenetics and pharmacoepigenomics of gastrointestinal cancers

References

• Torre LA, Siegel RL, Ward EM, et al. Global cancer incidence and mortality rates and trends-an update. Cancer Epidemiol Biomarkers Prev. 2016;25(1):16–27.
   PubMed Web of Science ®Google Scholar
• Sandoval J, Esteller M. Cancer epigenomics: beyond genomics. Curr Opin Genet Dev. 2012;22(1):50–55.
   PubMed Web of Science ®Google Scholar
• Migliore L, Migheli F, Spisni R, et al. Genetics, cytogenetics, and epigenetics of colorectal cancer. J Biomed Biotechnol. 2011;2011:1–19.
   Google Scholar
• Smits KM, Cleven AH, Weijenberg MP, et al. Pharmacoepigenomics in colorectal cancer: a step forward in predicting prognosis and treatment response. Pharmacogenomics. 2008;9(12):1903–1916.
   PubMed Web of Science ®Google Scholar
• Gherardini L, Sharma A, Capobianco E, et al. Targeting cancer with epi-drugs: a precision medicine perspective. Curr Pharm Biotechnol. 2016;17(10):856–865.
   PubMed Web of Science ®Google Scholar
• Mendiratta S, Jain S, Maini J, et al. Pharmacoepigenomics: an interplay of epigenetic modulation of drug response and modulation of the epigenome by drugs. Curr Pharm Des. 2014;20(11):1819–1830.
   PubMed Web of Science ®Google Scholar
• Martín-Subero JI. How epigenomics brings phenotype into being. Pediatr Endocrinol Rev. 2011;9(Suppl. 1):506–510.
   PubMedGoogle Scholar
• Abdelfatah E, Kerner Z, Nanda N, et al. Epigenetic therapy in gastrointestinal cancer: the right combination. Therap Adv Gastroenterol. 2016;9(4):560–579.
   PubMed Web of Science ®Google Scholar
• Miousse IR, Koturbash I. The fine LINE: methylation drawing the cancer landscape. Biomed Res Int. 2015;2015:131547.
   PubMed Web of Science ®Google Scholar
• Bannister AJ, Kouzarides T. Regulation of chromatin by histone modifications. Cell Res. 2011;21(3):381–395.
   PubMed Web of Science ®Google Scholar
• Berger SL. The complex language of chromatin regulation during transcription. Nature. 2007;447(7143):407–412.
   PubMed Web of Science ®Google Scholar
• Coppedè F. The role of epigenetics in colorectal cancer. Expert Rev Gastroenterol Hepatol. 2014;8(8):935–948.
   PubMed Web of Science ®Google Scholar
• He Y, Lin J, Kong D, et al. Current state of circulating MicroRNAs as cancer biomarkers. Clin Chem. 2015;61(9):1138–1155.
   PubMed Web of Science ®Google Scholar
• Huarte M. The emerging role of lncRNAs in cancer. Nat Med. 2015;21(11):1253–1261.
   PubMed Web of Science ®Google Scholar
• Huang T, Lin C, Zhong LL, et al. Targeting histone methylation for colorectal cancer. Therap Adv Gastroenterol. 2017;10(1):114–131.
   PubMed Web of Science ®Google Scholar
• Torre LA, Bray F, Siegel RL, et al. Global cancer statistics, 2012. CA Cancer J Clin. 2015;65(2):87–108.
   PubMed Web of Science ®Google Scholar
• Colussi D, Brandi G, Bazzoli F, et al. Molecular pathways involved in colorectal cancer: implications for disease behavior and prevention. Int J Mol Sci. 2013;14(8):16365–16385.
   PubMed Web of Science ®Google Scholar
• Kocarnik JM, Shiovitz S, Phipps AI. Molecular phenotypes of colorectal cancer and potential clinical applications. Gastroenterol Rep (Oxf). 2015;3(4):269–276.
   PubMed Web of Science ®Google Scholar
• Xie T, Huang M, Wang Y, et al. MicroRNAs as regulators, biomarkers and therapeutic targets in the drug resistance of colorectal cancer. Cell Physiol Biochem. 2016;40(1–2):62–76.
   PubMed Web of Science ®Google Scholar
• Karapetis CS, Khambata-Ford S, Jonker DJ, et al. K-ras mutations and benefit from cetuximab in advanced colorectal cancer. N Engl J Med. 2008;359:1757–1765.
   PubMed Web of Science ®Google Scholar
• Di Nicolantonio F, Martini M, Molinari F, et al. Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer. J Clin Oncol. 2008;26:5705–5712.
   PubMed Web of Science ®Google Scholar
• Ellis LM, Hicklin DJ. VEGF-targeted therapy: mechanisms of anti-tumour activity. Nat Rev Cancer. 2008;8:579–591.
   PubMed Web of Science ®Google Scholar
• Coppedè F, Lopomo A, Spisni R, et al. Genetic and epigenetic biomarkers for diagnosis, prognosis and treatment of colorectal cancer. World J Gastroenterol. 2014;20(4):943–956.
   PubMed Web of Science ®Google Scholar
• Ebert MP, Tanzer M, Balluff B, et al. TFAP2E–DKK4 and chemoresistance in colorectal cancer. N Engl J Med. 2012;366(1):44–53.
   PubMed Web of Science ®Google Scholar
• Beggs AD, Dilworth MP, Domingo E, et al. Methylation changes in the TFAP2E promoter region are associated with BRAF mutation and poorer overall & disease free survival in colorectal cancer. Oncoscience. 2015;2(5):508–516.
   PubMedGoogle Scholar
• Crea F, Nobili S, Paolicchi E, et al. Epigenetics and chemoresistance in colorectal cancer: an opportunity for treatment tailoring and novel therapeutic strategies. Drug Resist Updat. 2011;14(6):280–296.
   PubMed Web of Science ®Google Scholar
• Xie FW, Peng YH, Wang WW, et al. Influence of UGT1A1 gene methylation level in colorectal cancer cells on the sensitivity of the chemotherapy drug CPT-11. Biomed Pharmacother. 2014;68(7):825–831.
   PubMed Web of Science ®Google Scholar
• Cheetham S, Tang MJ, Mesak F, et al. SPARC promoter hypermethylation in colorectal cancers can be reversed by 5-Aza-2ʹdeoxycytidine to increase SPARC expression and improve therapy response. Br J Cancer. 2008;98(11):1810–1819.
   PubMed Web of Science ®Google Scholar
• Hiraki M, Kitajima Y, Nakafusa Y, et al. CpG island methylation of BNIP3 predicts resistance against S-1/CPT-11 combined therapy in colorectal cancer patients. Oncol Rep. 2010;23(1):191–197.
   PubMed Web of Science ®Google Scholar
• Baharudin R, Ab Mutalib NS, Othman SN, et al. Identification of predictive DNA methylation biomarkers for chemotherapy response in colorectal cancer. Front Pharmacol. 2017;8:47.
   PubMed Web of Science ®Google Scholar
• Shen Y, Tong M, Liang Q, et al. Epigenomics alternations and dynamic transcriptional changes in responses to 5-fluorouracil stimulation reveal mechanisms of acquired drug resistance of colorectal cancer cells. Pharmacogenomics J. 2017.
   Google Scholar
• Jiang G, Lin J, Wang W, et al. WNT5A promoter methylation is associated with better responses and longer progression-free survival in colorectal cancer patients treated with 5-fluorouracil-based chemotherapy. Genet Test Mol Biomarkers. 2017;21(2):74–79.
   PubMed Web of Science ®Google Scholar
• Kubiliūtė R, Šulskytė I, Daniūnaitė K, et al. Molecular features of doxorubicin-resistance development in colorectal cancer CX-1 cell line. Medicina (Kaunas). 2016;52(5):298–306.
   PubMed Web of Science ®Google Scholar
• Herbst A, Vdovin N, Gacesa S, et al. Methylated free-circulating HPP1 DNA is an early response marker in patients with metastatic colorectal cancer. Int J Cancer. 2017;140(9):2134–2144.
   PubMed Web of Science ®Google Scholar
• Pfutze K, Benner A, Hoffmeister M, et al. Methylation status at HYAL2 predicts overall and progression-free survival of colon cancer patients under 5-FU chemotherapy. Genomics. 2015;106(6):348–354.
   PubMed Web of Science ®Google Scholar
• Minoo P. Toward a molecular classification of colorectal cancer: the role of MGMT. Front Oncol. 2013;3:266.
   PubMedGoogle Scholar
• Coppedè F, Migheli F, Lopomo A, et al. Gene promoter methylation in colorectal cancer and healthy adjacent mucosa specimens: correlation with physiological and pathological characteristics, and with biomarkers of one-carbon metabolism. Epigenetics. 2014;9(4):621–633.
   PubMed Web of Science ®Google Scholar
• Sartore-Bianchi A, Pietrantonio F, Amatu A, et al. Digital PCR assessment of MGMT promoter methylation coupled with reduced protein expression optimises prediction of response to alkylating agents in metastatic colorectal cancer patients. Eur J Cancer. 2017;71:43–50.
   PubMed Web of Science ®Google Scholar
• Barrow TM, Michels KB. Epigenetic epidemiology of cancer. Biochem Biophys Res Commun. 2014;455(1–2):70–83.
   PubMed Web of Science ®Google Scholar
• Suzuki H, Yamamoto E, Maruyama R, et al. Biological significance of the CpG island methylator phenotype. Biochem Biophys Res Commun. 2014;455(1–2):35–42.
   PubMed Web of Science ®Google Scholar
• Kawakami K, Matsunoki A, Kaneko M, et al. Long interspersed nuclear element-1 hypomethylation is a potential biomarker for the prediction of response to oral fluoropyrimidines in microsatellite stable and CpG island methylator phenotype-negative colorectal cancer. Cancer Sci. 2011;102(1):166–174.
   PubMed Web of Science ®Google Scholar
• Jia M, Gao X, Zhang Y, et al. Different definitions of CpG island methylator phenotype and outcomes of colorectal cancer: a systematic review. Clin Epigenetics. 2016;8:25.
   PubMed Web of Science ®Google Scholar
• Ogino S, Nishihara R, VanderWeele TJ, et al. Review article: the role of molecular pathological epidemiology in the study of neoplastic and non-neoplastic diseases in the era of precision medicine. Epidemiology. 2016;27(4):602–611.
   PubMed Web of Science ®Google Scholar
• Okugawa Y, Grady WM, Goel A. Epigenetic alterations in colorectal cancer: emerging biomarkers. Gastroenterology. 2015;149(5):1204–1225.
   PubMed Web of Science ®Google Scholar
• Nijhuis A, Thompson H, Adam J, et al. Remodelling of microRNAs in colorectal cancer by hypoxia alters metabolism profiles and 5-fluorouracil resistance. Hum Mol Genet. 2017;26(8):1552–1564.
   PubMed Web of Science ®Google Scholar
• Fu Q, Cheng J, Zhang J, et al. miR-20b reduces 5-FU resistance by suppressing the ADAM9/EGFR signaling pathway in colon cancer. Oncol Rep. 2017;37(1):123–130.
   PubMed Web of Science ®Google Scholar
• Liu N, Li J, Zhao Z, et al. MicroRNA-302a enhances 5-fluorouracil-induced cell death in human colon cancer cells. Oncol Rep. 2017;37(1):631–639.
   PubMed Web of Science ®Google Scholar
• Jiang H, Ju H, Zhang L, et al. microRNA-577 suppresses tumor growth and enhances chemosensitivity in colorectal cancer. J Biochem Mol Toxicol. 2017;31:e21888.
   Web of Science ®Google Scholar
• Wu H, Liang Y, Shen L, et al. MicroRNA-204 modulates colorectal cancer cell sensitivity in response to 5-fluorouracil-based treatment by targeting high mobility group protein A2. Biol Open. 2016;5(5):563–570.
   PubMed Web of Science ®Google Scholar
• Wan LY, Deng J, Xiang XJ, et al. miR-320 enhances the sensitivity of human colon cancer cells to chemoradiotherapy in vitro by targeting FOXM1. Biochem Biophys Res Commun. 2015;457(2):125–132.
   PubMed Web of Science ®Google Scholar
• Liu X, Xie T, Mao X, et al. MicroRNA-149 increases the sensitivity of colorectal cancer cells to 5-fluorouracil by targeting forkhead box transcription factor FOXM1. Cell Physiol Biochem. 2016;39(2):617–629.
   PubMed Web of Science ®Google Scholar
• Peng L, Zhu H, Wang J, et al. MiR-492 is functionally involved in Oxaliplatin resistance in colon cancer cells LS174T via its regulating the expression of CD147. Mol Cell Biochem. 2015;405(1–2):73–79.
   PubMed Web of Science ®Google Scholar
• Guo Y, Pang Y, Gao X, et al. MicroRNA-137 chemosensitizes colon cancer cells to the chemotherapeutic drug oxaliplatin (OXA) by targeting YBX1. Cancer Biomark. 2017;18(1):1–9.
   PubMed Web of Science ®Google Scholar
• Bitarte N, Bandres E, Boni V, et al. MicroRNA-451 is involved in the self-renewal, tumorigenicity, and chemoresistance of colorectal cancer stem cells. Stem Cells. 2011;29:1661–1671.
   PubMed Web of Science ®Google Scholar
• Faltejskova P, Besse A, Sevcikova S, et al. Clinical correlations of miR-21 expression in colorectal cancer patients and effects of its inhibition on DLD1 colon cancer cells. Int J Colorectal Dis. 2012;27(11):1401–1408.
   PubMed Web of Science ®Google Scholar
• Khorrami S, Zavaran Hosseini A, Mowla SJ, et al. MicroRNA-146a induces immune suppression and drug-resistant colorectal cancer cells. Tumour Biol. 2017;39(5):1010428317698365.
   Web of Science ®Google Scholar
• Hansen TF, Carlsen AL, Heegaard NH, et al. Changes in circulating microRNA-126 during treatment with chemotherapy and bevacizumab predicts treatment response in patients with metastatic colorectal cancer. Br J Cancer. 2015;112(4):624–629.
   PubMed Web of Science ®Google Scholar
• Azad NS, El-Khoueiry A, Yin J, et al. Combination epigenetic therapy in metastatic colorectal cancer (mCRC) with subcutaneous 5-azacitidine and entinostat; a phase 2 consortium/stand Up 2 cancer study. Oncotarget. 2017;8:35326–35338.
   PubMed Web of Science ®Google Scholar
• Yang D, Torres CM, Bardhan K, et al. Decitabine and vorinostat cooperate to sensitize colon carcinoma cells to Fas ligand-induced apoptosis in vitro and tumor suppression in vivo. J Immunol. 2012;188(9):4441–4449.
   PubMed Web of Science ®Google Scholar
• Flis S, Gnyszka A, Flis K. DNA methyltransferase inhibitors improve the effect of hemotherapeutic agents in SW48 and HT-29 colorectal cancer cells. PLoS One. 2014;9(3):e92305.
   PubMed Web of Science ®Google Scholar
• Sharma A, Vatapalli R, Abdelfatah E, et al. Hypomethylating agents synergize with irinotecan to improve response to chemotherapy in colorectal cancer cells. PLoS One. 2017;12(4):e0176139.
   PubMed Web of Science ®Google Scholar
• Garrido-Laguna I, McGregor KA, Wade M, et al. A phase I/II study of decitabine in combination with panitumumab in patients with wild-type (wt) KRAS metastatic colorectal cancer. Invest New Drugs. 2013;31(5):1257–1264.
   PubMed Web of Science ®Google Scholar
• Lou YF, Zou ZZ, Chen PJ, et al. Combination of gefitinib and DNA methylation inhibitor decitabine exerts synergistic anti-cancer activity in colon cancer cells. PLoS One. 2014;9(5):e97719.
   PubMed Web of Science ®Google Scholar
• Paschall AV, Yang D, Lu C, et al. H3K9 trimethylation silences fas expression to confer colon carcinoma immune escape and 5-fluorouracil chemoresistance. J Immunol. 2015;195(4):1868–1882.
   PubMed Web of Science ®Google Scholar
• Anandappa G, Chau I. Emerging novel therapeutic agents in the treatment of patients with gastroesophageal and gastric adenocarcinoma. Hematol Oncol Clin North Am. 2017;31(3):529–544.
   PubMed Web of Science ®Google Scholar
• Jeon MS, Song SH, Yun J, et al. Aberrant epigenetic modifications of LPHN2 function as a potential cisplatin-specific biomarker for human gastrointestinal cancer. Cancer Res Treat. 2016;48(2):676–686.
   PubMedGoogle Scholar
• Derks S, Cleven AH, Melotte V, et al. Emerging evidence for CHFR as a cancer biomarker: from tumor biology to precision medicine. Cancer Metastasis Rev. 2014;33(1):161–171.
   PubMed Web of Science ®Google Scholar
• Li Y, Yang Y, Lu Y, et al. Predictive value of CHFR and MLH1 methylation in human gastric cancer. Gastric Cancer. 2015;18(2):280–287.
   PubMed Web of Science ®Google Scholar
• Pan Y, Lin S, Xing R, et al. Epigenetic upregulation of metallothionein 2A by diallyl trisulfide enhances chemosensitivity of human gastric cancer cells to docetaxel through attenuating NF-κB activation. Antioxid Redox Signal. 2016;24(15):839–854.
   PubMed Web of Science ®Google Scholar
• Riquelme I, Letelier P, Riffo-Campos AL, et al. Emerging role of miRNAs in the drug resistance of gastric cancer. Int J Mol Sci. 2016;17(3):424.
   PubMed Web of Science ®Google Scholar
• Li C, Zou J, Zheng G, et al. MiR-30a decreases multidrug resistance (MDR) of gastric cancer cells. Med Sci Monit. 2016;22:4509–4515.
   PubMed Web of Science ®Google Scholar
• Lu C, Shan Z, Li C, et al. MiR-129 regulates cisplatin-resistance in human gastric cancer cells by targeting P-gp. Biomed Pharmacother. 2017;86:450–456.
   PubMed Web of Science ®Google Scholar
• Jian B, Li Z, Xiao D, et al. Downregulation of microRNA-193-3p inhibits tumor proliferation migration and chemoresistance in human gastric cancer by regulating PTEN gene. Tumour Biol. 2016;37(7):8941–8949.
   PubMed Web of Science ®Google Scholar
• Cao W, Wei W, Zhan Z, et al. MiR-1284 modulates multidrug resistance of gastric cancer cells by targeting EIF4A1. Oncol Rep. 2016;35(5):2583–2591.
   PubMed Web of Science ®Google Scholar
• Ge X, Liu X, Lin F, et al. MicroRNA-421 regulated by HIF-1α promotes metastasis, inhibits apoptosis, and induces cisplatin resistance by targeting E-cadherin and caspase-3 in gastric cancer. Oncotarget. 2016;7(17):24466–24482.
   PubMed Web of Science ®Google Scholar
• Jia X, Li N, Peng C, et al. miR-493 mediated DKK1 down-regulation confers proliferation, invasion and chemo-resistance in gastric cancer cells. Oncotarget. 2016;7(6):7044–7054.
   PubMed Web of Science ®Google Scholar
• Teng R, Hu Y, Zhou J, et al. Overexpression of Lin28 decreases the chemosensitivity of gastric cancer cells to oxaliplatin, paclitaxel, doxorubicin, and fluorouracil in part via microRNA-107. PLoS One. 2015;10(12):e0143716.
   PubMed Web of Science ®Google Scholar
• Zhang N, Wang AY, Wang XK, et al. GAS5 is downregulated in gastric cancer cells by promoter hypermethylation and regulates adriamycin sensitivity. Eur Rev Med Pharmacol Sci. 2016;20(15):3199–3205.
   PubMed Web of Science ®Google Scholar
• Jackson K, Soutto M, Peng D, et al. Epigenetic silencing of somatostatin in gastric cancer. Dig Dis Sci. 2011;56:1125–30.
   Web of Science ®Google Scholar
• Shi X, Li X, Chen L, et al. Analysis of somatostatin receptors and somatostatin promoter methylation in human gastric cancer. Oncol Lett. 2013;6(6):1794–1798.
   PubMed Web of Science ®Google Scholar
• Zouridis H, Deng N, Ivanova T, et al. Methylation subtypes and large-scale epigenetic alterations in gastric cancer. Sci Transl Med. 2012;4(156):156ra140.
   PubMedGoogle Scholar
• Tan W, Zhou W, Yu HG, et al. The DNA methyltransferase inhibitor zebularine induces mitochondria-mediated apoptosis in gastric cancer cells in vitro and in vivo. Biochem Biophys Res Commun. 2013;430(1):250–255.
   PubMed Web of Science ®Google Scholar
• Chang H, Rha S, Jeung H, et al. Identification of genes related to a synergistic effect of taxane and suberoylanilide hydroxamic acid combination treatment in gastric cancer cells. J Cancer Res Clin Oncol. 2010;136(12):901–913.
   Web of Science ®Google Scholar
• Shah MA. Future directions in improving outcomes for patients with gastric and esophageal cancer. Hematol Oncol Clin North Am. 2017;31(3):545–552.
   PubMed Web of Science ®Google Scholar
• Yun T, Liu Y, Gao D, et al. Methylation of CHFR sensitizes esophageal squamous cell cancer to docetaxel and paclitaxel. Genes Cancer. 2015;6(1–2):38–48.
   PubMedGoogle Scholar
• Scolnick DM, Halazonetis TD. Chfr defines a mitotic stress checkpoint that delays entry into metaphase. Nature. 2000;406(6794):430–435.
   PubMed Web of Science ®Google Scholar
• Takahashi T, Yamahsita S, Matsuda Y, et al. ZNF695 methylation predicts a response of esophageal squamous cell carcinoma to definitive chemoradiotherapy. J Cancer Res Clin Oncol. 2015;141(3):453–463.
   PubMed Web of Science ®Google Scholar
• Li SQ, Chen FJ, Cao XF. Distinctive microRNAs in esophageal tumor: early diagnosis, prognosis judgment, and tumor treatment. Dis Esophagus. 2013;26(3):288–298.
   PubMed Web of Science ®Google Scholar
• Odenthal M, Bollschweiler E, Grimminger PP, et al. MicroRNA profiling in locally advanced esophageal cancer indicates a high potential of miR-192 in prediction of multimodality therapy response. Int J Cancer. 2013;133(10):2454–2463.
   PubMed Web of Science ®Google Scholar
• Hong L, Han Y, Zhang H, et al. The prognostic and chemotherapeutic value of miR-296 in esophageal squamous cell carcinoma. Ann Surg. 2010;251(6):1056–1063.
   PubMed Web of Science ®Google Scholar
• Zhang H, Li M, Han Y, et al. Down-regulation of miR-27a might reverse multidrug resistance of esophageal squamous cell carcinoma. Dig Dis Sci. 2010;55(9):2545–2551.
   PubMed Web of Science ®Google Scholar
• Hummel R, Watson DI, Smith C, et al. Impact of miRNAs on sensitivity to anticancer treatment in sensitive and resistant esophageal squamous cell carcinoma cell lines. Dis Esophagus. 2010;23:48A–9A.
   Google Scholar
• Imanaka Y, Tsuchiya S, Sato F, et al. MicroRNA-141 confers resistance to cisplatin induced apoptosis by targeting YAP1 in human esophageal squamous cell carcinoma. J Hum Genet. 2011;56(4):270–276.
   PubMed Web of Science ®Google Scholar
• Hamano R, Miyata H, Yamasaki M, et al. Overexpression of miR-200c induces chemoresistance in esophageal cancers mediated through activation of the Akt signaling pathway. Clin Cancer Res. 2011;17(9):3029–3038.
   PubMed Web of Science ®Google Scholar
• Wang Y, Zhao Y, Herbst A, et al. miR-221 mediates chemoresistance of esophageal adenocarcinoma by direct targeting of DKK2 expression. Ann Surg. 2016;264(5):804–814.
   PubMed Web of Science ®Google Scholar
• Jin YY, Chen QJ, Xu K, et al. Involvement of microRNA-141-3p in 5-fluorouracil and oxaliplatin chemo-resistance in esophageal cancer cells via regulation of PTEN. Mol Cell Biochem. 2016;422(1–2):161–170.
   PubMed Web of Science ®Google Scholar
• Lynam-Lennon N, Heavey S, Sommerville G, et al. MicroRNA-17 is downregulated in esophageal adenocarcinoma cancer stem-like cells and promotes a radioresistant phenotype. Oncotarget. 2017;8(7):11400–11413.
   PubMed Web of Science ®Google Scholar
• Pan F, Mao H, Bu F, et al. Sp1-mediated transcriptional activation of miR-205 promotes radioresistance in esophageal squamous cell carcinoma. Oncotarget. 2017;8(4):5735–5752.
   PubMed Web of Science ®Google Scholar
• Jingjing L, Wangyue W, Qiaoqiao X, et al. MiR-218 increases sensitivity to cisplatin in esophageal cancer cells via targeting survivin expression. Open Med (Wars). 2016;11(1):31–35.
   PubMedGoogle Scholar
• Wang X, Wang J, Jia Y, et al. Methylation decreases the Bin1 tumor suppressor in ESCC and restoration by decitabine inhibits the epithelial mesenchymal transition. Oncotarget. 2017;8(12):19661–19673.
   PubMed Web of Science ®Google Scholar
• Tzao C, Jin JS, Chen BH, et al. Anticancer effects of suberoylanilide hydroxamic acid in esophageal squamous cancer cells in vitro and in vivo. Dis Esophagus. 2014;27(7):693–702.
   PubMed Web of Science ®Google Scholar
• Ma J, Guo X, Zhang S, et al. Trichostatin A, a histone deacetylase inhibitor, suppresses proliferation and promotes apoptosis of esophageal squamous cell lines. Molecular Medicine Reports. 2015;11(6):4525–4531.
   PubMed Web of Science ®Google Scholar
• Ahrens T, Timme S, Hoeppner J, et al. Selective inhibition of esophageal cancer cells by combination of HDAC inhibitors and azacytidine. Epigenetics. 2015;10(5):431–445.
   PubMed Web of Science ®Google Scholar
• Weiser T, Guo Z, Ohnmacht G, et al. Sequential 5-Aza-2 deoxycytidine-depsipeptide FR901228 treatment induces apoptosis preferentially in cancer cells and facilitates their recognition by cytolytic T lymphocytes specific for NY-ESO-1. J Immunother. 2001;24(2):151–161.
   PubMed Web of Science ®Google Scholar
• Weiser T, Ohnmacht G, Guo Z, et al. Induction of MAGE-3 expression in lung and esophageal cancer cells. Ann Thorac Surg. 2001;71(1):295–301.
   PubMed Web of Science ®Google Scholar
• Hoshino I, Matsubara H, Akutsu Y, et al. Role of histone deacetylase inhibitor in adenovirus-mediated P53 gene therapy in esophageal cancer. Anticancer Res. 2008;28(2A):665–671.
   PubMed Web of Science ®Google Scholar
• Ma J, Zhao J, Lu J, et al. Coxsackievirus and adenovirus receptor promotes antitumor activity of oncolytic adenovirus H101 in esophageal cancer. Int J Mol Med. 2012;30(6):1403–1409.
   PubMed Web of Science ®Google Scholar
• Schneider BJ, Shah MA, Klute K, et al. Phase I study of epigenetic priming with azacitidine prior to standard neoadjuvant chemotherapy for patients with resectable gastric and esophageal adenocarcinoma. Clin Cancer Res. 2016;23:2673–2680.
   PubMed Web of Science ®Google Scholar
• Kamisawa T, Wood LD, Itoi T, et al. Pancreatic cancer. Lancet. 2016;388(10039):73–85.
   PubMed Web of Science ®Google Scholar
• Suker M, Beumer BR, Sadot E, et al. FOLFIRINOX for locally advanced pancreatic cancer: a systematic review and patient-level meta-analysis. Lancet Oncol. 2016;17(6):801–810.
   PubMed Web of Science ®Google Scholar
• Wang X, Xu J, Wang H, et al. Trichostatin A, a histone deacetylase inhibitor, reverses epithelial–mesenchymal transition in colorectal cancer SW480 and prostate cancer PC3 cells. Biochem Biophys Res Commun. 2015;456(1):320–326.
   PubMed Web of Science ®Google Scholar
• Pan MR, Hsu MC, Luo CW, et al. The histone methyltransferase G9a as a therapeutic target to override gemcitabine resistance in pancreatic cancer. Oncotarget. 2016;7(38):61136–61151.
   PubMed Web of Science ®Google Scholar
• Guo Q, Qin W. DKK3 blocked translocation of β-catenin/EMT induced by hypoxia and improved gemcitabine therapeutic effect in pancreatic cancer Bxpc-3 cell. J Cell Mol Med. 2015;19(12):2832–2841.
   PubMed Web of Science ®Google Scholar
• Ramachandran K, Miller H, Gordian E, et al. Methylation-mediated silencing of TMS1 in pancreatic cancer and its potential contribution to chemosensitivity. Anticancer Res. 2010;30(10):3919–3925.
   PubMed Web of Science ®Google Scholar
• Schmitt AM, Pavel M, Rudolph T, et al. Prognostic and predictive roles of MGMT protein expression and promoter methylation in sporadic pancreatic neuroendocrine neoplasms. Neuroendocrinology. 2014;100(1):35–44.
   PubMed Web of Science ®Google Scholar
• Walter T, van Brakel B, Vercherat C, et al. O6-Methylguanine-DNA methyltransferase status in neuroendocrine tumours: prognostic relevance and association with response to alkylating agents. Br J Cancer. 2015;112(3):523–531.
   PubMed Web of Science ®Google Scholar
• Zhao L, Zou D, Wei X, et al. MiRNA-221-3p desensitizes pancreatic cancer cells to 5-fluorouracil by targeting RB1. Tumour Biol. 2016;37:16053–16063.
   Web of Science ®Google Scholar
• Xia X, Zhang K, Luo G, et al. Downregulation of miR-301a-3p sensitizes pancreatic cancer cells to gemcitabine treatment via PTEN. Am J Transl Res. 2017;9(4):1886–1895.
   PubMed Web of Science ®Google Scholar
• Mikamori M, Yamada D, Eguchi H, et al. MicroRNA-155 controls exosome synthesis and promotes gemcitabine resistance in pancreatic ductal adenocarcinoma. Sci Rep. 2017;7:42339.
   PubMed Web of Science ®Google Scholar
• Xu J, Wang T, Cao Z, et al. MiR-497 downregulation contributes to the malignancy of pancreatic cancer and associates with a poor prognosis. Oncotarget. 2014;5(16):6983–6993.
   PubMed Web of Science ®Google Scholar
• Liang C, Yu XJ, Guo XZ, et al. MicroRNA-33amediated downregulation of pim-3 kinase expression renders human pancreatic cancer cells sensitivity to gemcitabine. Oncotarget. 2015;6(16):14440–14445.
   PubMed Web of Science ®Google Scholar
• Toste PA, Li L, Kadera BE, et al. p85α is a microRNA target and affects chemosensitivity in pancreatic cancer. J Surg Res. 2015;196(2):285–293.
   PubMed Web of Science ®Google Scholar
• Lin Y, Ge X, Wen Y, et al. MiRNA-145 increases therapeutic sensibility to gemcitabine treatment of pancreatic adenocarcinoma cells. Oncotarget. 2016;7(43):70857–70868.
   PubMed Web of Science ®Google Scholar
• Trehoux S, Lahdaoui F, Delpu Y, et al. Micro-RNAs miR-29a and miR-330-5p function as tumor suppressors by targeting the MUC1 mucin in pancreatic cancer cells. Biochim Biophys Acta. 2015;1853(10 Pt A):2392–2403.
   PubMed Web of Science ®Google Scholar
• Zhan Q, Fang Y, Deng X, et al. The interplay between miR-148a and DNMT1 might be exploited for pancreatic cancer therapy. Cancer Invest. 2015;33(7):267–275.
   PubMed Web of Science ®Google Scholar
• Zhang H, Chen L, Bu HQ, et al. Effects of emodin on the demethylation of tumor-suppressor genes in pancreatic cancer PANC-1 cells. Oncol Rep. 2015;33(6):3015–3023.
   PubMed Web of Science ®Google Scholar
• Wang X, Wang H, Jiang N, et al. Effect of inhibition of MEK pathway on 5-aza-deoxycytidine-suppressed pancreatic cancer cell proliferation. Genet Mol Res. 2013;12(4):5560–5573.
   PubMed Web of Science ®Google Scholar
• Hessmann E, Johnsen SA, Siveke JT, et al. Epigenetic treatment of pancreatic cancer: is there a therapeutic perspective on the horizon? Gut. 2017;66(1):168–179.
   PubMed Web of Science ®Google Scholar
• Wang YH, Sui YN, Yan K, et al. BRD4 promotes pancreatic ductal adenocarcinoma cell proliferation and enhances gemcitabine resistance. Oncol Rep. 2015;33(4):1699–1706.
   PubMed Web of Science ®Google Scholar
• Meidhof S, Brabletz S, Lehmann W, et al. ZEB1-associated drug resistance in cancer cells is reversed by the class I HDAC inhibitor mocetinostat. EMBO Mol Med. 2015;7(6):831–847.
   PubMed Web of Science ®Google Scholar
• Mazur PK, Herner A, Mello SS, et al. Combined inhibition of BET family proteins and histone deacetylases as a potential epigenetics-based therapy for pancreatic ductal adenocarcinoma. Nat Med. 2015;21(10):1163–1171.
   PubMed Web of Science ®Google Scholar
• Yang SZ, Xu F, Zhou T, et al. The long non-coding RNA HOTAIR enhances pancreatic cancer resistance to TNF-related apoptosis inducing ligand. J Biol Chem. 2017;292:10390–10397.
   PubMed Web of Science ®Google Scholar